Vertex CEO Reshma Kewalramani Leads CRISPR Revolution as Pharma's Top Women Executives Reshape the Industry
核心洞察
Under CEO Reshma Kewalramani, Vertex launched Casgevy, the first FDA-approved CRISPR (搜索) gene-editing drug, and Journavx, a new class of non-opioid painkillers.
Vertex posted $12 billion in profit in 2025 with a market capitalization exceeding $100 billion, expanding beyond cystic fibrosis (搜索) into neurological, hematological, and renal diseases.
Bahija Jallal rescued Immunocore (搜索) from near-collapse, raised $130 million, and secured FDA approval for Kimmtrak, the world's first therapy for inoperable or metastatic uveal melanoma (搜索).
Reshma Kewalramani, CEO of Vertex Pharmaceuticals, has cemented her position at the forefront of the pharmaceutical industry by steering the company to landmark achievements in gene editing and pain management. Under her leadership, Vertex launched Casgevy — the first FDA-approved drug based on CRISPR (搜索) gene-editing technology, developed in partnership with CRISPR Therapeutics — and in early 2025 secured FDA approval for Journavx, ushering in a new class of non-opioid painkillers.
Vertex's strategy of first understanding the biology of a disease and then finding the right tool to address it has delivered remarkable financial results: the company posted $12 billion in profit in 2025 and achieved a market capitalization exceeding $100 billion. The R&D portfolio has expanded beyond cystic fibrosis (搜索), which remains the core of the business, to include neurological, hematological, and renal diseases. A recent partnership with Enlaza Therapeutics has opened an autoimmune therapy pipeline.
Kewalramani's path to the top reflects a deliberate pivot from clinical practice to drug development. With a medical degree from Boston University, she spent 12 years at Amgen before joining Vertex in 2017. She became chief medical officer a year later, and two years after that was promoted to CEO.
Immunocore's Turnaround Under Bahija Jallal
When Bahija Jallal took over as head of Immunocore (搜索) in 2019, the company was on the brink of collapse — it had only six months of funding left, and the CEO position had been vacant for two years. Jallal, a biochemist who joined from AstraZeneca, was drawn by promising science that lacked financial backing.
On her first day as CEO, she began negotiations with investors, and within less than a year, Immunocore (搜索) raised $130 million. Despite the COVID-19 pandemic in 2020, the company continued enrolling patients in clinical trials and went public on Nasdaq in 2021, raising $297 million. The company's T-cell receptor therapy, Kimmtrak, received FDA approval in early 2021 as the world's first therapy for inoperable or metastatic uveal melanoma (搜索). Immunocore now plans to expand beyond oncology into infectious and autoimmune diseases, including HIV.
GSK's US Commercial Momentum
Maya Martinez-Davis, president of GSK's US division, oversaw the launch of five new drugs in 2025 alone. Martinez-Davis began her career at France's Rhône-Poulenc, whose pharma division was later acquired by Sanofi. Her first mentor was Belén Garijo, CEO of Merck KGaA, who pushed her to take her first international assignment in Paris. Emma Walmsley, CEO of GSK, later helped Martinez-Davis adapt to the realities of working at the British pharmaceutical company.
AI-Driven Drug Development and Diagnostics
The industry is also seeing transformation through artificial intelligence. In early 2026, a new CEO and president took the helm at Recursion, an AI-driven biotech, after previously serving as chief R&D officer and chief commercial officer overseeing the full cycle of operations since 2024. The executive's path included seven years at Boston Consulting Group, where she became a partner working with major pharma and biotech companies, followed by roles at Johnson & Johnson in data analytics and investment decisions.
In diagnostics, Dr. Minetta Liu, chief medical officer for oncology at Natera, is advancing liquid biopsy technology. One of Natera's tests is in the pre-approval stage with the FDA as a companion diagnostic for patients with muscle-invasive bladder cancer (搜索). Liu, who previously spent a decade in academic medicine at the Mayo Clinic, joined Natera in 2022 to advance the company's cancer blood-test pipeline, focusing on developing tests to reduce recurrence rates in patients who have already undergone treatment.
At-Home Cervical Cancer Screening Breakthrough
Kara Egan, CEO and co-founder of Teal Health (搜索), has addressed a persistent public health gap: despite the proven link between screening and reduced cervical cancer (搜索) incidence, one in four women in the United States does not get screened. After five years of prototype development, Teal Health launched Teal Wand — the first FDA-approved at-home cervical cancer screening kit. Egan, who previously worked in medtech investment and software product marketing, collaborated with Dr. Avnesh Thakor, who had already developed a prototype of a home-based sample collection device.
Leadership Across Therapeutic Frontiers
Kristen Loch, senior vice president and head of biology at Nimbus Therapeutics (搜索), oversees oncology, liver disease, and metabolic disorder research. With a PhD in immunology from Harvard Medical School and a postdoc at MIT, Loch previously worked at Icos (later acquired by Eli Lilly), spent six and a half years at Pfizer, and held roles at Sirtris Pharmaceuticals and Biogen before joining Nimbus, where she has spent over six years.
At Dispatch Bio (搜索), Barbara Sasu leads project selection, utilizing the company's proprietary Flare platform, which delivers a universal antigen that labels solid tumor cells while dismantling cancer's resistance mechanisms. The labeled tumor cells then activate the immune system. The company initially planned to focus on CAR-T therapy but sees potential to expand to other mechanisms of action.
Lina Polimeni, Eli Lilly's chief consumer marketing officer with over 20 years at the company, launched the company's first corporate campaign in over a century in 2021, integrating the brand into cultural moments including the Olympics, the Oscars, and the Grammys. She also led efforts that helped Eli Lilly achieve gender parity in its executive ranks.
Laura Lande-Diner, managing partner at Jefferson Life Sciences, co-founded Valo Health, which focuses on AI-driven drug development, and holds more than a dozen patents. She now works with MIT's Faculty Founders initiative, helping women professors turn research into businesses — a program created because women faculty members are far less likely to start companies than men.